Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
PPMX-T004b-PGAP-1、PPMX-T004
Applicable field (uses covered by this announcement)
Solid tumors, including ovarian cancer, biliary tract cancer and head and neck squamous cell carcinoma
Launch datePM on 24 September 2026 (scheduled): planned academic conference presentation
Relationship between the counterparty and the company
Perseus Proteomics Inc.4882
Relationship with the Company
Joint research relationship
CounterpartyUBE Corporation
Head office: Minato-ku, Tokyo; Representative Director and President: Nishida Yuki (西田祐樹). Other company information: Not disclosed
Location (as indicated in this announcement)
Kyoto International Conference Center
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PPMX-T004b-PGAP-1、PPMX-T004 |
| Counterparty | UBE Corporation |
| Counterparty overview | Head office: Minato-ku, Tokyo; Representative Director and President: Nishida Yuki (西田祐樹). Other company information: Not disclosed |
| Relationship with the Company | Joint research relationship |
| Launch date | PM on 24 September 2026 (scheduled): planned academic conference presentation |
| Applicable area | Solid tumors, including ovarian cancer, biliary tract cancer and head and neck squamous cell carcinoma |
| Location | Kyoto International Conference Center |
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results of the joint research project were accepted for presentation in the poster session at the annual meeting.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.